Diagnostic research: a quick review

Madhukar Pai, MD, PhD
Assistant Professor of Epidemiology, McGill University
Montreal, Canada
Editor, Cochrane Infectious Diseases Group (CIDG)

Email: madhukar.pai@mcgill.ca
Diagnosis: why does it matter?

To effectively practice medicine and public health, we need evidence/knowledge on 3 fundamental types of professional knowing “gnosis”:

- Dia-gnosis
- Etio-gnosis
- Pro-gnosis

Dia-gnosis
Etio-gnosis
Pro-gnosis

Dia-gnosis
Etio-gnosis
Pro-gnosis

For individual (Clinical Medicine)

For community (Public and community health)

Miettinen OS
Approaches to Diagnosis

Consider the following diagnostic situations:

- A 43-year-old woman presents with a painful cluster of vesicles grouped in the T3 dermatome of her left thorax.
- A 78-year-old man returns to the office for follow-up of hypertension. He has lost 10 kg since his last visit 4 months ago. He describes reduced appetite, but otherwise, there are no localizing symptoms. You recall that his wife died a year ago and consider depression as a likely explanation, yet his age and exposure history (ie, smoking) suggest other possibilities.
# Approaches to Diagnosis

<table>
<thead>
<tr>
<th>Pattern recognition</th>
<th>Probabilistic diagnostic reasoning</th>
</tr>
</thead>
<tbody>
<tr>
<td>See it and recognize disorder</td>
<td>Clinical assessment generates pretest probability</td>
</tr>
<tr>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>Compare posttest probability with thresholds</td>
<td>New information generates posttest probability</td>
</tr>
<tr>
<td>(usually pattern recognition implies probability near 100% and so above threshold)</td>
<td>(may be interactive)</td>
</tr>
<tr>
<td></td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td>Compare posttest probability with thresholds</td>
</tr>
</tbody>
</table>


Copyright © American Medical Association. All rights reserved.
Misdiagnosis is common!

Most misguided care results from thinking errors rather than technical mistakes.

Major thinking traps: "three As"

- Anchoring
  - Shortcut in thinking when a person doesn’t consider multiple possibilities but quickly latches on to a single one.

- Availability
  - Tendency to judge the likelihood of an event by the ease with which relevant examples come to mind.

- Attribution
  - Based on stereotypes that are based on someone’s appearance, emotional state or circumstances

Key question to avoid these traps: “What else can it be?”

"Usually doctors are right, but conservatively about 15 percent of all people are misdiagnosed. Some experts think it's as high as 20 to 25 percent," - Groopman
Process of diagnosis: all about probability and decision making under uncertainty!

<table>
<thead>
<tr>
<th>Test</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Threshold</td>
<td>Threshold</td>
</tr>
</tbody>
</table>

- 0%: No Tests
- 100%: Need to Test
- 100%: Treat

Probability of Diagnosis
Thresholds for decision-making: when will you stop investigating? when will you test further? when will you rule out disease?

Above this point, treat

Below this point, no further testing

Disease ruled IN

Disease not ruled in or out

Disease ruled OUT
The Perfect Diagnostic Test

X
No Disease

Y
Diseased
Variations In Diagnostic Tests

Overlap

Range of Variation in Disease free

Range of Variation in Diseased
Example: intra-ocular pressure

Overlap of distributions of intraocular pressure among those with glaucoma and those without glaucoma

Riegelman & Hirsch 1996
Example: WBC count in bacteremia

Figure 4.4  Histogram showing distributions of the nonbacteremic and bacteremic populations across the WBC count intervals.
There is no perfect test!

LII. An Essay towards solving a Problem in the Doctrine of Chances. By the late Rev. Mr. Bayes, communicated by Mr. Price, in a letter to John Canton, M. A. and F. R. S.

Dear Sir,

Read Dec. 23, 1763. I now send you an essay which I have found among the papers of our deceased friend Mr. Bayes, and which, in my opinion, has great merit, and well deserves to be preserved. Experimental philosophy, you will find, is nearly interested in the subject of it; and on this account there seems to be particular reason for thinking that a communication of it to the Royal Society cannot be improper.

He had, you know, the honour of being a member of that illustrious Society, and was much esteemed by many as a very able mathematician. In an introduction which he has writ to this Essay, he says, that his design at first in thinking on the subject of it was, to find out a method by which we might judge concerning the probability that an event has to happen, in given circumstances, upon supposition that we know nothing concerning it but that, under the same circumstances, it has happened a certain number of times, and failed a certain other number of times. He adds, that he soon perceived that it would not be very difficult to do this, provided some rule could be found, according to which we ought to estimate the chance that the probability for the happening of an event perfectly unknown, should lie between any two named degrees of prob-

All we can hope to do is increase or decrease probabilities, and Bayes’ theorem helps with this process.
Bayes' theory

- Bayes' Theorem is a simple mathematical formula used for calculating conditional probabilities.
- Every test is done with a certain probability of disease - degree of suspicion [pre-test or prior probability].
- The probability of disease after the test result is the post-test or posterior probability.

Post-test odds = Pre-test odds x Likelihood ratio

pre-test probability → Test → post-test probability
The most simplistic way of explaining Bayes’ theorem

What you thought before + New information = What you think now

Bayesian approach to diagnosis

- An accurate test will help reduce uncertainty.
- The pre-test probability is revised using test result to get the post-test probability.
- Tests that produce the biggest changes from pretest to post-test probabilities are most useful in clinical practice [very large or very small likelihood ratios].
- LR also called “Bayes Factor”
The diagnostic process is probabilistic, multivariable and sequential

1. A diagnosis starts with a patient presenting a complaint (symptom and/or sign) suggestive of a certain disease to be diagnosed.

2. The subsequent work-up is a multivariable process. It involves multiple diagnostic determinants (tests) that are applied in a logical order: from age, gender, medical history, and signs and symptoms, to more complicated, invasive, and costly tests.

3. Setting or ruling out a diagnosis is a probabilistic action in which the probability of the presence or absence of the disease is central. This probability is continuously updated based on subsequent diagnostic test results.

4. The true diagnostic value of a test is determined by the extent to which it provides diagnostic information beyond earlier tests, that is, materially changes the probability estimation of disease presence based on previous test results.

5. The goal of the diagnostic process is to eventually rule in or out the disease with enough confidence to take clinical decisions. This requires precise estimates of the probability of the presence of the target disease(s).

A diagnostic ‘test’ can be:

- A question (e.g. asking about a symptom)
- A simple physical sign
- A laboratory or imaging or other test
- A combination of many tests (e.g. a risk score or clinical prediction rule)
- An entire algorithm
Accuracy of perception and touch for detecting fever in adults: a hospital-based study from a rural, tertiary hospital in Central India

Manoj Singh¹, Madhukar Pai² and S. P. Kalantri¹

¹ Department of Medicine, Mahatma Gandhi Institute of Medical Sciences, Sevagram, India
² Division of Epidemiology, University of California at Berkeley, Berkeley, CA 94720, USA


Accuracy and reliability of physical signs in the diagnosis of pleural effusion

Shriprakash Kalantri¹, Rajnish Joshi¹, Trunal Lokhande¹, Amandeep Singh¹, Maureen Morgan¹, John M. Colford Jr¹, Madhukar Pai¹, *
Simple clinical predictors of brain lesions in patients with impaired consciousness: a cross sectional study from a rural, tertiary hospital in central India

Y. Geetadevi\textsuperscript{a, 1}, Rajnish Joshi\textsuperscript{a, 1}, Madhukar Pai\textsuperscript{b, 2}, S.P. Kalantri\textsuperscript{a, *}

\textsuperscript{a} Department of Medicine, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Wardha 442102, India

Original Articles

Poor accuracy of the Siriraj and Guy’s hospital stroke scores in distinguishing haemorrhagic from ischaemic stroke in a rural, tertiary care hospital

PRIYA BADAM, VAISHALI SOLAO, MADHUKAR PAI, S. P. KALANTRI
Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study

P. Daley,* J. S. Michael,† P. Hmar,‡ A. Latha,* P. Chordia,* D. Mathai,* K. R. John,‡ M. Pai§

*Department of Medicine, †Department of Microbiology, and ‡Department of Community Health, Christian Medical College, Vellore, India; §Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada

Evaluation of Diagnostic Accuracy, Feasibility and Client Preference for Rapid Oral Fluid-Based Diagnosis of HIV Infection in Rural India

Nitika Pant Pai1, Rajnish Joshi2, Sandeep Dogra3, Bharati Taksande2, S. P. Kalantri2, Madhukar Pai4, Pratibha Narang2, Jacqueline P. Tulsky5, Arthur L. Reingold6

1 Immunodeficiency Service, Montreal Chest Institute, McGill University Health Center, Montreal, Canada, 2Mahatma Gandhi Institute of Medical Sciences, Sevagram, Maharashtra, India, 3Acharya Shri Chander College of Medical Sciences, Jammu, India, 4Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada, 5Department of Internal Medicine, University of California at San Francisco, San Francisco, California, United States of America, 6Division of Epidemiology, University of California at Berkeley, Berkeley, California, United States of America
Diagnosis vs. prediction

Diagnosis:
- Disease has already occurred and we are trying to detect its presence

Prognosis:
- Disease has not occurred and we want to know who is most likely to develop the disease

Both are amenable to multivariable approaches and prediction models

They are often mixed up
- Sometimes a diagnostic test itself can be used to predict future outcomes (e.g. PSA)
Types of diagnostic study designs
Evidence base of clinical diagnosis

The architecture of diagnostic research

D L Sackett, R B Haynes

Considerable effort has been expended at the interface between clinical medicine and scientific methods to achieve the maximum validity and usefulness of diagnostic tests. This article focuses on the specific kinds of questions that arise in diagnostic research and the study architectures (the conversions of these clinical questions into appropriate research designs) used to answer them. As an example we shall take shall take assessment of the value of the plasma concentration of B-type natriuretic peptide (BNP) in the diagnosis of left ventricular dysfunction. Randomised controlled trials are dealt with elsewhere.

As in other forms of clinical research, there are several different ways studying the potential or real diagnostic value of a physical sign or laboratory test, and each is appropriate to one kind of question and inappropriate for others. Among the possible questions about the relation between a putative diagnostic test and a target disorder (for example, the concentration of BNP and left ventricular dysfunction), four are most relevant.

Types of question

Phase I questions
Do test results in patients with the target disorder differ from those in normal individuals? Table 1 shows the architecture of this question.

For example, investigators at a British university hospital measured concentrations of BNP precursor in non-systematic (“convenience”) samples from normal controls and from patients who had various combina-

Summary points

Diagnostic studies should match methods to diagnostic questions

- Do test results in affected patients differ from those in normal individuals?
- Are patients with certain test results more likely to have the target disorder?
- Do test results distinguish patients with and without the target disorder among those in whom it is clinically sensible to suspect the disorder?
- Do patients undergoing the diagnostic test fare better than similar untreated patients?

The keys to validity in diagnostic test studies are

- independent, blind comparison of test results with a reference standard among a consecutive series of patients suspected (but not known) to have the target disorder
- inclusion of missing and indeterminate results
- replication of studies in other settings

Both specificity and sensitivity may change as the same diagnostic test is applied in primary, secondary, and tertiary care.
Phase I to IV diagnostic studies

Phase I questions

- Do test results in patients with the target disorder differ from those in normal people?

**Table 1** Answering a phase I question: do patients with left ventricular dysfunction have higher concentrations of B-type natriuretic peptide (BNP) precursor than normal individuals?

<table>
<thead>
<tr>
<th>Patients known to have disorder</th>
<th>Normal controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (range) concentration of BNP precursor (pg/ml)</td>
<td>493.5 (248.9-909.0)</td>
</tr>
</tbody>
</table>

*BMJ* 2002;324:539–41
Phase I to IV diagnostic studies

**Phase II questions (test accuracy)**

- Are patients with certain test results more likely to have the target disorder than patients with other test results?

### Table 2
Answering a phase II question: are patients with higher concentrations of B-type natriuretic peptide (BNP) more likely to have left ventricular dysfunction than patients with lower concentrations?

<table>
<thead>
<tr>
<th></th>
<th>Patients known to have target disorder</th>
<th>Normal controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>High BNP concentration</td>
<td>39</td>
<td>2</td>
</tr>
<tr>
<td>Normal BNP concentration</td>
<td>1</td>
<td>25</td>
</tr>
</tbody>
</table>

Test characteristics (95% CI):
- Sensitivity = 98% (87% to 100%)
- Specificity = 92% (77% to 98%)
- Positive predictive value = 95% (84% to 99%)
- Negative predictive value = 96% (81% to 100%)
- Likelihood ratio for an abnormal test result = 13 (3.5 to 50.0)
- Likelihood ratio for a normal test result = 0.03 (0.0003 to 0.19)

*BMJ* 2002;324:539–41
Phase I to IV diagnostic studies

**Phase III questions (test accuracy)**

- Does the test result distinguish patients with and without the target disorder among patients in whom it is clinically reasonable to suspect that the disease is present?

| Table 3 Answering a phase III question: among patients in whom it is clinically sensible to suspect left ventricular dysfunction (LVD), does the concentration of B-type natriuretic peptide (BNP) distinguish patients with and without left ventricular dysfunction? |
|---------------------------------|------------------|------------------|
| **Concentration of BNP:**       | **Patients with LVD on echocardiography** | **Patients with normal results on echocardiography** |
| High (>17.9 pg/ml)              | 35               | 57               |
| Normal (<18 pg/ml)              | 5                | 29               |
| Prevalence (pretest probability) of LVD | 40/126=32%     |                  |
| **Test characteristics (95% CI):** |                  |                  |
| Sensitivity=88% (74% to 94%)    |                  |                  |
| Specificity=34% (25% to 44%)    |                  |                  |
| Positive predictive value=38% (29% to 48%) |          |                  |
| Negative predictive value=85% (70% to 94%) |          |                  |
| Likelihood ratio for an abnormal test result=1.3 (1.1 to 1.6) |          |                  |
| Likelihood ratio for a normal test result=0.4 (0.2 to 0.9) |          |                  |

*BMJ 2002;324:539–41*
Phase I to IV diagnostic studies

Phase IV questions ("impact")

- Do patients who undergo this diagnostic test fare better (in their ultimate health outcomes) than similar patients who are not tested?
DOES DIAGNOSTIC TEST ACCURACY TRANSLATE INTO IMPACT ON PATIENT OUTCOMES?
Evaluation of Diagnostic Accuracy, Feasibility and Client Preference for Rapid Oral Fluid-Based Diagnosis of HIV Infection in Rural India

Nitika Pant Pai1*, Rajnish Joshi2, Sandeep Dogra3, Bharati Taksande3, S. P. Kalantri2, Madhukar Pai4, Pratibha Narang3, Jacqueline P. Tulsky5, Arthur L. Reingold6

1 Immunodeficiency Service, Montreal Chest Institute, McGill University Health Center, Montreal, Canada, 2 Mahatma Gandhi Institute of Medical Sciences, Sevagram, Maharashtra, India, 3 Acharya Shri Chandra College of Medical Sciences, Jammu, India, 4 Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada, 5 Department of Internal Medicine, University of California at San Francisco, San Francisco, California, United States of America, 6 Division of Epidemiology, University of California at Berkeley, Berkeley, California, United States of America

Background. Oral fluid-based rapid tests are promising for improving HIV diagnosis and screening. However, recent reports from the United States of false-positive results with the oral OraQuick® ADVANCE HIV1/2 test have raised concerns about their performance in routine practice. We report a field evaluation of the diagnostic accuracy, client preference, and feasibility for the oral fluid-based OraQuick® Rapid HIV1/2 test in a rural hospital in India. Methodology/Principal Findings. A cross-sectional, hospital-based study was conducted in 450 consenting participants with suspected HIV infection in rural India. The objectives were to evaluate performance, client preference and feasibility of the OraQuick® Rapid HIV1-2 tests. Two OraQuick® Rapid HIV1/2 tests (oral fluid and finger stick) were administered in parallel with confirmatory ELISA/Western Blot (reference standard). Pre- and post-test counseling and face to face interviews were conducted to determine client preference. Of the 450 participants, 146 were deemed to be HIV sero-positive using the reference standard (seropositivity rate of 32% (95% confidence interval [CI] 28%, 37%)). The OraQuick test on oral fluid specimens had better performance with a sensitivity of 100% (95% CI 98, 100) and a specificity of 100% (95% CI 99, 100), as compared to the OraQuick test on finger stick specimens with a sensitivity of 100% (95% CI 98, 100), and a specificity of 99.7% (95% CI 98.4, 99.9). The OraQuick oral fluid-based test was preferred by 87% of the participants for first time testing and 60% of the participants for repeat testing. Conclusion/Significance. In a rural Indian hospital setting, the OraQuick® Rapid HIV1/2 test was found to be highly accurate. The oral fluid-based test performed marginally better than the finger stick test. The oral OraQuick test was highly preferred by participants. In the context of global efforts to scale-up HIV testing, our data suggest that oral fluid-based rapid HIV testing may work well in rural, resource-limited settings.

Impact of Round-the-Clock, Rapid Oral Fluid HIV Testing of Women in Labor in Rural India

Nitika Pant Pai1, Ritu Barick2, Jacqueline P. Tulskey3, Poonam V. Shivkumar2, Deborah Cohan3, Shripakash Kalanti2, Madhukar Pai4, Marina B. Klein1, Shakuntala Chhabra5

1 Division of Infectious Diseases and Immunodeficiency Service, Montreal Chest Institute, McGill University Health Center, Montreal, Canada, 2 Mahatma Gandhi Institute of Medical Sciences, Savagram, Wardha, Maharashtra, India, 3 Positive Health Program, Division of Internal Medicine, University of California San Francisco, San Francisco, California, United States of America, 4 Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada

Methods and Findings

After they provided written informed consent, women admitted to the labor ward of a rural teaching hospital in India were offered two rapid tests on oral fluid and finger-stick specimens (OraQuick Rapid HIV-1/HIV-2 tests, OraSure Technologies). Simultaneously, venous blood was drawn for conventional HIV ELISA testing. Western blot tests were performed for confirmatory testing if women were positive by both rapid tests and dual ELISA, or where test results were discordant. Round-the-clock (24 h, 7 d/wk) abbreviated prepartum and extended postpartum counseling sessions were offered as part of the testing strategy. HIV-positive women were administered PMTCT interventions. Of 1,252 eligible women (age range 18 y to 38 y) approached for consent over a 9 mo period in 2006, 1,222 (98%) accepted HIV testing in the labor ward. Of these, 1,003 (82%) women presented with either no reports or incomplete reports of prior HIV testing results at the time of admission to the labor ward. Of 1,222 women, 15 were diagnosed as HIV-positive (on the basis of two rapid tests, dual ELISA and Western blot), yielding a seroprevalence of 1.23% (95% confidence interval [CI] 0.61%–1.8%). Of the 15 HIV-test–positive women, four (27%) had presented with reported HIV status, and 11 (73%) new cases of HIV infection were detected due to rapid testing in the labor room. Thus, 11 HIV-positive women received PMTCT interventions on account of round-the-clock rapid HIV testing and counseling in the labor room. While both OraQuick tests (oral and finger-stick) were 100% specific, one false-negative result was documented (with both oral fluid and finger-stick specimens). Of the 15 HIV-infected women who delivered, 13 infants were HIV seronegative at birth and at 1 and 4 mo after delivery; two HIV-positive infants died within a month of delivery.

Conclusions

In a busy rural labor ward setting in India, we demonstrated that it is feasible to introduce a program of round-the-clock rapid HIV testing, including prepartum and extended postpartum counseling sessions. Our data suggest that the availability of round-the-clock rapid HIV testing resulted in successful documentation of HIV serostatus in a large proportion (82%) of rural women who were unaware of their HIV status when admitted to the labor room. In addition, 11 (73%) of a total of 15 HIV-positive women received PMTCT interventions because of round-the-clock rapid testing in the labor ward. These findings are relevant for PMTCT programs in developing countries.
SOMETIMES, NO!

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

B-Type Natriuretic Peptide Testing, Clinical Outcomes, and Health Services Use in Emergency Department Patients With Dyspnea

A Randomized Trial

Hans-Gerhard Schneider, MBBS, MD; Louisa Lam, MPH; Amaali Lokuge, MBBS; Henry Krum, MBBS, PhD; Matthew T. Naughton, MBBS; Pieter De Villiers Smit, MBBS; Adam Bystrzycki, MBBS; David Eccleston, MBBS, PhD; Jacob Federman, MBBS; Genevieve Flannery, MBBS; and Peter Cameron, MBBS, MD

**Background:** B-type natriuretic peptide (BNP) is used to diagnose heart failure, but the effects of using the test on all dyspneic patients is uncertain.

**Objective:** To assess whether BNP testing alters clinical outcomes and health services use of acutely dyspneic patients.

**Design:** Randomized, single-blind study. Patients were assigned to a treatment group through randomized numbers in a sealed envelope. Patients were blinded to the intervention, but clinicians and those who assessed trial outcomes were not.

**Setting:** 2 Australian teaching hospital emergency departments

**Patients:** 612 consecutive patients who presented with acute severe dyspnea from August 2005 to March 2007.

**Intervention:** BNP testing (n = 306) or no testing (n = 306).

**Measurements:** Admission rates, length of stay, and emergency department medications (primary outcomes); mortality and readmission rates (secondary outcomes).

**Results:** There were no between-group differences in hospital admission rates (85.6% [BNP group] vs. 86.6% [control group]; difference, −1.0 percentage point [95% CI, −6.5 to 4.5 percentage points]; P = 0.73), length of admission (median, 4.4 days [interquartile range, 2 to 9 days] vs. 5.0 days [interquartile range, 2 to 9 days]; P = 0.94), or management of patients in the emergency department. Test discrimination was good (area under the receiver-operating characteristic curve, 0.87 [CI, 0.83 to 0.91]). Adverse events were not measured.

**Limitation:** Most patients were very short of breath and required hospitalization; the findings might not apply for evaluating patients with milder degrees of breathlessness.

**Conclusion:** Measurement of BNP in all emergency department patients with severe shortness of breath had no apparent effects on clinical outcomes or use of health services. The findings do not support routine use of BNP testing in all severely dyspneic patients in the emergency department.

**Primary Funding Source:** Janssen-Cilag.
A slightly different classification

Evidence based diagnostics
Christian Glaud, Lis Lotts Glaud

Diagnostic tests are often much less rigorously evaluated than new drugs. It is time to ensure that the harms and benefits of new tests are fully understood.

No international consensus exists on the methods for assessing diagnostic tests. Previous recommendations stress that studies of diagnostic tests should match the type of diagnostic question. Once the specificity and sensitivity of a test have been established, the final question is whether tested patients fare better than similar untreated patients. This usually requires a randomised trial. Few tests are currently evaluated in this way. In this paper, we propose an architecture for research into diagnostic tests that parallels the established phases in drug research.

Stages of research

We have divided studies of diagnostic tests into four phases (Box). We use research on brain natriuretic peptide for diagnosing heart failure as an illustrative example. However, the architecture is applicable to a measure brain natriuretic peptide in human plasma, phase I studies were done to establish the normal range of values in healthy participants.

Diagnostic phase I studies must be large enough to examine the potential influence of characteristics such as sex, age, time of day, physical activity, and exposure to drugs. The studies are relatively quick, cheap, and easy to conduct, but they may occasionally raise ethical problems—for example, finding abnormal results in an apparently healthy person.

Diagnostic accuracy

In phase II, studies explore the diagnostic accuracy of a test in participants with both known and suspected relevant disease. Phase IIa studies compare test results in participants with disease diagnosed by a standard method with those in healthy participants (from

Four phases in architecture of diagnostic research

Phase I—Determining the normal range of values for a diagnostic test though observational studies in healthy people

Phase II—Determining the diagnostic accuracy through case-control studies, including healthy people and (a) people with known disease assessed by diagnostic standard and (b) people with suspected disease

Phase III—Determining the clinical consequences of introducing a diagnostic test through randomised trials

Phase IV—Determining the effects of introducing a new diagnostic test into clinical practice by surveillance in large cohort studies
Diagnostic RCTs


Randomised comparisons of medical tests: sometimes invalid, not always efficient

Patrick M M Bossuyt, Jeroen G Lijmer, Ben W J Mol

Figure 1: Trial designs of a single test
IUGR = intrauterine growth retardation; R = randomisation process.

Figure 2: Trial designs to compare two tests
IHD = ischaemic heart disease; PTCA = percutaneous transluminal coronary angioplasty; R = randomisation process. Abnormal scintigraphy = reversible perfusion defect; abnormal intracoronary flow velocity = insufficient reserve.
Diagnostic RCT: is it really diagnostic?

When performing a randomized trial to determine the impact of a diagnostic test or strategy on patient outcome, an initially diagnostic research question is transformed into therapeutic research question (with the goal of establishing causality) with corresponding consequences for the design of the study. A disadvantage of a randomized approach to directly quantify the contribution of a diagnostic test and treatment on patient outcome is that it often addresses diagnosis and treatment as a single combined strategy, a “package deal.” This makes it impossible to determine afterwards whether a positive effect on patient outcome was attributed solely to the improved diagnosis by using the test under study or to the chosen (new) treatment strategies.

Diagnostic study design

Two generic ways in which a test or diagnostic strategy can be evaluated. On the left, patients are randomised to a new test or strategy or to an old test or strategy. Those with a positive test result (cases detected) are randomised (or were previously randomised) to receive the best available management (second step of randomisation for management not shown). Investigators evaluate and compare patient-important outcomes in all patients in both groups. On the right, patients receive both a new test and a reference test (old or comparator test or strategy). Investigators can then calculate the accuracy of the test compared with the reference test (first step). To make judgments about importance to patients of this information, patients with a positive test (or strategy) in either group are (or have been in previous studies) submitted to treatment or no treatment; investigators then evaluate and compare patient-important outcomes in all patients in both groups (second step).

Example
Consistent evidence from well designed studies shows fewer false negative results with non-contrast helical computed tomography (CT) than with intravenous pyelography (IVP) in the diagnosis of suspected acute urolithiasis. However, the stones in the ureter that CT detects but IVP "misses" are smaller, and hence are likely to pass more easily. As RCTs evaluating the outcomes in patients treated for smaller stones are not available, the extent to which reduction in cases that are missed (false negatives) and follow-up of incidental findings unrelated to renal calculi with CT have important health benefits remains uncertain.

Example
Randomised control trials (RCTs) explored a diagnostic strategy guided by the use of B type natriuretic peptide (BNP)—designed to aid diagnosis of heart failure—compared with no use of BNP in patients presenting to the emergency department with acute dyspnoea. As it turned out, the group randomised to receive BNP spent a shorter time in the hospital at lower cost, with no increased mortality or morbidity.
Two key properties of any test

- Accuracy (also called ‘validity’)
- Precision (also called ‘reliability’ or ‘reproducibility’)

Precision and Accuracy
Precision and Accuracy
Precision and Accuracy

The Rational Clinical Examination
Copyright © American Medical Association. All rights reserved. | JAMA | The McGraw-Hill Companies, Inc.
Quantifying precision

Observer Variation

• Intraobserver agreement
  Does the same clinician get the same result when repeating a symptom or sign on a patient who is clinically unchanged?

• Interobserver agreement
  Do 2 or more observers agree on the presence or absence of a finding in a patient who experienced no change in condition?

• Kappa (κ)
  Agreement beyond chance and can be used to describe both intra- and interobserver agreement

Note: Other measures are used for continuous measurements (e.g. correlation coefficient, limits of agreement, etc)
Quantifying accuracy

- Sensitivity and Specificity
- Likelihood ratios
- Positive and Negative Predictive Value
- Diagnostic Odds Ratio
Tests with dichotomous results
A standard Phase II/III diagnostic design for accuracy estimation

- Define gold standard
- Recruit consecutive patients in whom the test is indicated (in whom the disease is suspected)
- Perform gold standard and separate diseased and disease free groups
- Perform test on all and classify them as test positives or negatives
- Set up 2 x 2 table and compute:
  - Sensitivity
  - Specificity
  - Predictive values
  - Likelihood ratios
  - Diagnostic odds ratio
Evaluating a diagnostic test

- Diagnostic 2 X 2 table*:

<table>
<thead>
<tr>
<th></th>
<th>Disease +</th>
<th>Disease -</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Test +</strong></td>
<td>True Positive</td>
<td>False Positive</td>
</tr>
<tr>
<td><strong>Test -</strong></td>
<td>False Negative</td>
<td>True Negative</td>
</tr>
</tbody>
</table>

*When test results are not dichotomous, then can use ROC curves [see later]*
Sensitivity
[true positive rate]

The proportion of patients with disease who test positive = $P(T^+|D^+) = \frac{TP}{(TP+FN)}$
Specificity
[true negative rate]

<table>
<thead>
<tr>
<th></th>
<th>Disease present</th>
<th>Disease absent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test positive</td>
<td>True positives</td>
<td>False positives</td>
</tr>
<tr>
<td>Test negative</td>
<td>False negative</td>
<td>True negatives</td>
</tr>
</tbody>
</table>

The proportion of patients without disease who test negative: \( P(T^-|D^-) = \frac{TN}{TN + FP} \).
### Predictive value of a positive test

<table>
<thead>
<tr>
<th></th>
<th>Disease present</th>
<th>Disease absent</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Test positive</strong></td>
<td>True positives</td>
<td>False positives</td>
</tr>
<tr>
<td><strong>Test negative</strong></td>
<td>False negative</td>
<td>True negatives</td>
</tr>
</tbody>
</table>

Proportion of patients with positive tests who have disease $= P(D+|T+) = \frac{TP}{(TP+FP)}$
# Predictive value of a negative test

<table>
<thead>
<tr>
<th></th>
<th>Disease present</th>
<th>Disease absent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test positive</td>
<td>True positives</td>
<td>False positives</td>
</tr>
<tr>
<td>Test negative</td>
<td>False negative</td>
<td>True negatives</td>
</tr>
</tbody>
</table>

Proportion of patients with negative tests who do not have disease = \( P(D^-|T^-) = \frac{TN}{TN+FN} \)
**Example: Serological test for TB**

<table>
<thead>
<tr>
<th>Culture (gold standard)</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serological Test</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>14</td>
<td>3</td>
</tr>
<tr>
<td>Negative</td>
<td>54</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>68</td>
<td>31</td>
</tr>
</tbody>
</table>

Sensitivity = 21%
Specificity = 90%

*Clin Vacc Immunol 2006;13: 702-03*
For a given test, predictive values will depend on prevalence

Effect of Prevalence on Predictive Value: Positive Predictive Value of Prostatic Acid Phosphatase for Prostatic Cancer (Sensitivity = 70%, Specificity = 90%) in Various Clinical Settings*

<table>
<thead>
<tr>
<th>Setting</th>
<th>Prevalence (Cases/100,000)</th>
<th>Positive Predictive Value (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>General population</td>
<td>35</td>
<td>0.4</td>
</tr>
<tr>
<td>Men, age 75 or greater</td>
<td>500</td>
<td>5.6</td>
</tr>
<tr>
<td>Clinically suspicious prostatic nodule</td>
<td>50,000</td>
<td>93.0</td>
</tr>
</tbody>
</table>

For a given test, predictive values will depend on prevalence.

Positive predictive value according to sensitivity, specificity, and prevalence of disease.

Fletcher 1996
Likelihood Ratios (also called ‘Bayes Factor’)

• Likelihood ratio of a positive test: is the test more likely to be positive in diseased than non-diseased persons?

\[ LR^+ = \frac{TPR}{FPR} \]

• High LR+ values help in RULING IN the disease

• Values close to 1 indicate poor accuracy

• E.g. LR+ of 10 means a diseased person is 10 times more likely to have a positive test than a non-diseased person
Likelihood Ratio of a Positive Test

How more often a positive test result occurs in persons with compared to those without the target condition.

\[ LR^+ = \frac{\Pr(T+ | D+)}{\Pr(T+ | D-)} \]
Likelihood Ratios

- Likelihood ratio of a negative test: is the test less likely to be negative in the diseased than non-diseased persons?

\[ LR^- = \frac{\Pr(T^- | D^+)}{\Pr(T^- | D^-)} \]

- Low LR- values help in RULING OUT the disease
- Values close to 1 indicate poor accuracy
- E.g. LR- of 0.5 means a diseased person is half as likely to have a negative test than a non-diseased person
Likelihood Ratio of a Negative Test

<table>
<thead>
<tr>
<th></th>
<th>Disease present</th>
<th>Disease absent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test positive</td>
<td>True positives</td>
<td>False positives</td>
</tr>
<tr>
<td>Test negative</td>
<td>False negative</td>
<td>True negatives</td>
</tr>
</tbody>
</table>

How less likely a negative test result is in persons with the target condition compared to those without the target condition.

$$LR^- = \frac{\Pr(T- \mid D+)}{\Pr(T- \mid D-)}$$

$$LR^- = \frac{\text{FNR}}{\text{TNR}}$$
LR: Impact on Likelihood of Disease

LR = 0.01
LR = 0.1
LR = 0.2
LR = 0.3
LR = 1
LR = 3
LR = 5
LR = 10
LR = 100

Less
Less
Less
Less
More
More
More
More

Likely
Likely
Likely
Likely
Likely
Likely
Likely
Likely

LR = 0
LR = 1

Increasing impact
Increasing impact

The Rational Clinical Examination
Copyright © American Medical Association. All rights reserved. | JAMA | The McGraw-Hill Companies, Inc.
Quick review of odds vs. probability

\( \text{odds} = \frac{\text{probability}}{(1 - \text{probability})} \)

\[ \text{Odds}(D+) = \frac{\Pr(D+)}{1 - \Pr(D+)} \]

\( \text{probability} = \frac{\text{odds}}{(1 + \text{odds})} \)

\[ \Pr(D+) = \frac{\text{Odds}(D+)}{1 + \text{Odds}(D+)} \]
# Diagnostic Odds Ratio (DOR)

<table>
<thead>
<tr>
<th>Test outcome</th>
<th>Disease present</th>
<th>Disease absent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test positive</td>
<td>True positives (a)</td>
<td>False positives (b)</td>
</tr>
<tr>
<td>Test negative</td>
<td>False negative (c)</td>
<td>True negatives (d)</td>
</tr>
</tbody>
</table>

DOR = \( \frac{(a/c) \cdot (b/d)}{ad/bc} \)

DOR = Odds of T+|D+ / Odds of T+|D-
The diagnostic odds ratio: a single indicator of test performance

Afina S. Glasa,⁎, Jeroen G. Lijmerb, Martin H. Prinsc, Gouke J. Bonseld, Patrick M.M. Bossuyta

aDepartment of Clinical Epidemiology & Biostatistics, University of Amsterdam, Academic Medical Center, Post Office Box 22700, 100 DE Amsterdam, The Netherlands
bDepartment of Psychiatry, University Medical Center, Post Office Box 85500, 3508 GA, Utrecht, The Netherlands
cDepartment of Epidemiology, University of Maastricht, Post Office Box 6166200 MD, Maastricht, The Netherlands
dDepartment of Public Health, Academic Medical Center, Post Office Box 22700, 1100 DE, Amsterdam, The Netherlands

Accepted 17 April 2003

Abstract

Diagnostic testing can be used to discriminate subjects with a target disorder from subjects without it. Several indicators of diagnostic performance have been proposed, such as sensitivity and specificity. Using paired indicators can be a disadvantage in comparing the performance of competing tests, especially if one test does not outperform the other on both indicators. Here we propose the use of the odds ratio as a single indicator of diagnostic performance. The diagnostic odds ratio is closely linked to existing indicators, it facilitates formal meta-analysis of studies on diagnostic test performance, and it is derived from logistic models, which allow for the inclusion of additional variables to correct for heterogeneity. A disadvantage is the impossibility of weighing the true positive and false positive rate separately. In this article the application of the diagnostic odds ratio in test evaluation is illustrated. © 2003 Elsevier Inc. All rights reserved.
### Example: Serological test for TB

#### Culture (gold standard)

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>14</td>
<td>3</td>
</tr>
<tr>
<td>Negative</td>
<td>54</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>68</td>
<td>31</td>
</tr>
</tbody>
</table>

- LR+ = 2
- LR- = 0.9
- DOR = 2.4

*Clin Vacc Immunol 2006; 13: 702-03*
Using LRs in practice

Scenario:

- Mr. A, a 27-year old, recent immigrant male (from Viet Nam)
- Fever and productive cough for the past 3 weeks
- Lost weight
- Father had TB in the past
Assess the patient and estimate the baseline risk (pre-test probability)

Based on initial history, how likely is it that Mr. A has pulmonary tuberculosis?

How might the result of a serological test change the likelihood of TB in this patient?
Likelihood Ratios

Mr. A
Pre-Test Prob. 50%

Serological test
LR+ = 2

Pre-Test Probability
Post-Test Probability

Post-Test Prob. 70%

Probability
Pre-Test Prob.
Likelihood Ratios

Mr. A
Pre-Test Prob. 50%

Post-Test Prob. 45%

Serological test
LR- = 0.9
Using LRs in practice

Scenario:

- Ms. B, a 18 year old Canadian-born, McGill student
- Fever and non-productive cough for the past 4 days
- Nobody in the household has had TB
Ms. B
Pre-Test Prob. 10%

Post-Test Prob. 20%

Serological test
LR+ = 2
Likelihood Ratios

Ms. B Pre-Test Prob. 10%

Post-Test Prob. 10%

Serological test
LR- = 0.9
Example: Ultrasonography for Down Syndrome
Another example: Nuchal fold & Down Syndrome

<table>
<thead>
<tr>
<th>Nuchal fold</th>
<th>Positive</th>
<th>Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>21</td>
<td>7</td>
</tr>
<tr>
<td>No</td>
<td>4</td>
<td>188</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>192</td>
<td>220</td>
</tr>
</tbody>
</table>

Sensitivity = 75%
Specificity = 98%
LR+ = 36
LR- = 0.26
DOR = 141

Using LRs in practice

Scenario:
- Mrs. A, a 37-year old woman with a previous affected pregnancy, seen at a high-risk clinic in a tertiary, referral hospital
- What is the pretest probability of Down syndrome in this case?
Likelihood Ratios

Pre-Test Probability

Mrs. A Pre-Test Prob. 10%

Post-Test Probability

Post-Test Prob. 80%

Nuchal fold abnormal
LR = 36
Likelihood Ratios

Pre-Test Probability

Mrs. A
Pre-Test Prob. 10%

Post-Test Probability

Nuchal fold normal
LR = 0.26

Post-Test Prob. 3%
Using LRs in practice

Scenario:

- Mrs. B, a 20-year old woman with a previous normal pregnancy, seen at a community hospital

- What is the pretest probability of Down syndrome in this case?
Likelihood Ratios

Mrs. B
Pre-Test Prob. 0.5%
Nuchal fold abnormal
LR = 36

Post-Test Prob. 10%
Likelihood Ratios

Pre-Test Probability

Mrs. B
Pre-Test Prob. 0.5%

Nuchal fold normal
LR = 0.26

Post-Test Probability

Post-Test Prob. 0.1%
Where do we get LRs from?

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Pretest Probabilities and Likelihood Ratios for Clinical Findings
Quick Reference
http://jamaevidence.com

Note: Large images and tables on this page may necessitate printing in landscape mode.

The Rational Clinical Examination > Pretest Probabilities and Likelihood Ratios for Clinical Findings
Quick Reference

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Prior Probability</th>
<th>Test/Finding</th>
<th>LR+</th>
<th>LR-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter 1: Primer on Precision and Accuracy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chapter 2: Abdominal Aortic Aneurysm</td>
<td>Occur in 4% to 8% of older men. The prevalence in older women is less than 2%</td>
<td>Physical examination for aneurysm &gt; 4.0 cm</td>
<td>16 (8.6–29)</td>
<td>0.51 (0.38–0.67)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Physical examination for aneurysm &gt; 5.0 cm</td>
<td>12 (7.4–20)</td>
<td>0.72 (0.65–0.81)</td>
</tr>
<tr>
<td>Chapter 3:</td>
<td>Approximately 1% to 5% of the general population</td>
<td>Systolic-diastolic bruit</td>
<td>39 (10–145)</td>
<td>0.62 (0.49–0.73)</td>
</tr>
</tbody>
</table>
Are sens/spec and LRs inherent properties of a test?

- Most textbooks will say that sens and spec do not depend on disease prevalence.
- This is partly true but oversimplified.
- In reality, sens/spec and LRs vary across populations because of differences in disease spectra (case-mix) and several other factors.
- This is equivalent to “effect modification” in epidemiology.
Example

Sens and Spec across populations

Ex:
Sensitivity + specificity of serum CEA for detection of colorectal cancer, across stages

ROC curve for CEA as a diagnostic test for colorectal cancer, according to stage of disease. The sensitivity and specificity of a test vary with the stage of disease. (Redrawn from Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986;104:66–73.)
Tests with continuous or multi-level results
Example: WBC count in bacteremia

Figure 4.4  Histogram showing distributions of the nonbacteremic and bacteremic populations across the WBC count intervals.

Table 4.3. Sensitivity and specificity of the WBC count as a predictor of bacteremia at different cut-offs for considering the test “positive” (data from Lee and Harper 1998)

<table>
<thead>
<tr>
<th>WBC count interval (×1,000/μL)</th>
<th>Percent of bacteremia patients in interval</th>
<th>Percent of no bacteremia patients in interval</th>
<th>Sensitivity (using bottom of interval as cut-off)</th>
<th>1−Specificity (using bottom of interval as cut-off)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30</td>
<td>11.8%</td>
<td>0.8%</td>
<td>11.8%</td>
<td>0.8%</td>
</tr>
<tr>
<td>25 to &lt;30</td>
<td>9.4%</td>
<td>1.8%</td>
<td>21.3%</td>
<td>2.6%</td>
</tr>
<tr>
<td>20 to &lt;25</td>
<td>26.8%</td>
<td>5.4%</td>
<td>48.0%</td>
<td>8.0%</td>
</tr>
<tr>
<td>15 to &lt;20</td>
<td>37.8%</td>
<td>15.5%</td>
<td>85.8%</td>
<td>23.5%</td>
</tr>
<tr>
<td>10 to &lt;15</td>
<td>11.8%</td>
<td>32.1%</td>
<td>97.6%</td>
<td>55.6%</td>
</tr>
<tr>
<td>5 to &lt;10</td>
<td>2.4%</td>
<td>38.1%</td>
<td>100%</td>
<td>93.7%</td>
</tr>
<tr>
<td>0 to &lt;5</td>
<td>0.0%</td>
<td>6.3%</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>
Figure 4.5  ROC curve corresponding to the distributions in Figure 4.4.

Area Under Curve (AUC) = 0.86
Figure 4.2 Test discriminates poorly between patients with disease (D+) and patients without disease (D−). (A) The distribution of test results in D+ patients is very similar to the distribution in D− patients. (B) This “bad” ROC curve approaches a 45-degree diagonal line.

Figure 4.3 Test discriminates well between patients with the disease (D+) and patients without the disease (D−). (A) The distribution of test results in D+ patients differs substantially from the distribution in D− patients. (B) This “good” ROC curve nears the upper left corner of the grid.
Figure 4.6  Example of computer-drawn ROC curves, in which the cut-off for considering the test “abnormal” is systematically decreased from the highest to the lowest values observed in infants with and without bacterial meningitis. Note that two different WBC counts are considered: the WBC count in the cerebrospinal fluid, which discriminates fairly well between those with and without bacterial meningitis; and the WBC count in the peripheral blood, which discriminates poorly. (From Bonsu and Harper 2003, with permission.) AUC = Area Under Curve.
## Multi-level likelihood ratios

Table 4.4. Likelihood ratios for WBC and bacteremia (from Lee and Harper 1998)

<table>
<thead>
<tr>
<th>WBC Count (×1,000/μL)</th>
<th>Bacteremia</th>
<th>No bacteremia</th>
<th>LR</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–35</td>
<td>11.8%</td>
<td>0.8%</td>
<td>15.2</td>
</tr>
<tr>
<td>25–30</td>
<td>9.4%</td>
<td>1.8%</td>
<td>5.3</td>
</tr>
<tr>
<td>20–25</td>
<td>26.8%</td>
<td>5.4%</td>
<td>4.9</td>
</tr>
<tr>
<td>15–20</td>
<td>37.8%</td>
<td>15.5%</td>
<td>2.4</td>
</tr>
<tr>
<td>10–15</td>
<td>11.8%</td>
<td>32.1%</td>
<td>0.37</td>
</tr>
<tr>
<td>5–10</td>
<td>2.4%</td>
<td>38.1%</td>
<td>0.06</td>
</tr>
<tr>
<td>0–5</td>
<td>0.0%</td>
<td>6.3%</td>
<td>0.00</td>
</tr>
</tbody>
</table>

After understanding ROC curves, it should be obvious that

diamond the case of a dichotomous test accuracy (i.e. the usual 2 x 2 table) is merely a single point on some underlying ROC curve

diamond in other words, all tests have some underlying ROC curve

diamond we can easily change the sens/spec by shifting the point on the ROC curve

diamond this is critical for understanding diagnostic meta-analyses!
ROC: pros and cons

Pros:

- Provides a wholistic picture (a global assessment of a test’s accuracy)
- Not dependent on disease prevalence
- Does not force us to pick a single cut-off point
- Shows the trade off between sens and spec
- Great for comparing accuracy of competing tests
- Can be applied to any diagnostic system: weather forecasting, lie detectors, medical imaging, to detection of cracks in metals!
ROC: pros and cons

Cons:
- Not very intuitive for clinicians; the ROC and AUC cannot be directly used for any given patient.
- Clinicians prefer simple yes/no test results.
- You can have the same AUC, but different shapes.
- Does not easily fit into the EBM framework of working with LRs and probabilities.
- Very hard to meta-analyze.
Diagnostic systems of several kinds are used to distinguish between two classes of events, essentially “signals” and “noise.” For them, analysis in terms of the “relative operating characteristic” of signal detection theory provides a precise and valid measure of diagnostic accuracy. It is the only measure available that is uninfluenced by decision biases and prior probabilities, and it places the performances of diverse systems on a common, easily interpreted scale. Representative values of this measure are reported here for systems in medical imaging, materials testing, weather forecasting, information retrieval, polygraph lie detection, and aptitude testing. Though the measure itself is sound, the values obtained from tests of diagnostic systems often require qualification because the test data on which they are based are of unsure quality. A common set of problems in testing is faced in all fields. How well these problems are handled, or can be handled in a given field, determines the degree of confidence that can be placed in a measured value of accuracy. Some fields fare much better than others.

One or another inadequate or misleading way, a good way is available for general use. The preferred way quantifies accuracy independently of the relative frequencies of the events (conditions, objects) to be diagnosed (“disease” and “no disease” or “rain” and “no rain,” for instance) and also independently of the diagnostic system’s decision bias, that is, its particular tendency to choose one alternative over another (be it “disease” over “no disease,” or vice versa). In so doing, the preferred measure is more valid and precise than the alternatives and can place all diagnostic systems on a common scale.

On the other hand, good test data can be very difficult to obtain. Thus, the “truth” against which diagnostic decisions are scored may be less than perfectly reliable, and the sample of test cases selected may not adequately represent the population to which the system is applied in practice. Such problems occur generally across diagnostic fields, but with more or less severity depending on the field. Hence, our confidence in an assessment of accuracy can be higher in some fields than in others—higher, for instance, in weather forecasting than in polygraph lie detection.

James A. Hanley, Ph.D.
Barbara J. McNeil, M.D., Ph.D.

The Meaning and Use of the Area under a Receiver Operating Characteristic (ROC) Curve¹
Beyond diagnostic accuracy
Are sensitivity and specificity the most meaningful measures?

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
<th>Examples of Study Purpose or Measures</th>
<th>Studies Available, $n$</th>
<th>Patients, $n$</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Technical feasibility and optimization</td>
<td>Ability to produce consistent spectra</td>
<td>85</td>
<td>2434</td>
</tr>
<tr>
<td>2</td>
<td>Diagnostic accuracy</td>
<td>Sensitivity and specificity</td>
<td>8</td>
<td>461</td>
</tr>
<tr>
<td>3</td>
<td>Diagnostic thinking impact</td>
<td>Percentage of times clinicians' subjective assessment of diagnostic probabilities changed after the test</td>
<td>2</td>
<td>32</td>
</tr>
<tr>
<td>4</td>
<td>Therapeutic choice impact</td>
<td>Percentage of times therapy planned before MRS changed after the test</td>
<td>2</td>
<td>105</td>
</tr>
<tr>
<td>5</td>
<td>Patient outcome impact</td>
<td>Percentage of patients who improved with MRS diagnosis compared with those without MRS (e.g., survival, quality of life)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>Societal impact</td>
<td>Cost-effectiveness analysis (e.g., use to detect tumor in asymptomatic population)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

* MRS = magnetic resonance spectroscopy
RATING QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS

GRADE: grading quality of evidence and strength of recommendations for diagnostic tests and strategies

The GRADE system can be used to grade the quality of evidence and strength of recommendations for diagnostic tests or strategies. This article explains how patient-important outcomes are taken into account in this process.

SUMMARY POINTS

As for other interventions, the GRADE approach to grading the quality of evidence and strength of recommendations for diagnostic tests or strategies provides a comprehensive and transparent approach for developing recommendations.

Cross sectional or cohort studies can provide high quality evidence of test accuracy.

However, test accuracy is a surrogate for patient-important outcomes, so such studies often provide low quality evidence for recommendations about diagnostic tests, even when the studies do not have serious limitations.

Inferring from data on accuracy that a diagnostic test or strategy improves patient-important outcomes will require the availability of effective treatment, reduction of test related adverse effects or anxiety, or improvement of patients’ wellbeing from prognostic information.

Judgments are thus needed to assess the directness of test results in relation to consequences of diagnostic recommendations that are important to patients.
Redundancy of Single Diagnostic Test Evaluation

Karel G.M. Moons,1,2,3 Gerri-Anne van Es,4 Bowine C. Michel,5 Harry R. Bülter,6 J. Dik F. Habbema,3 and Diederick E. Grobbee1

Diagnostic research

Diagnostic studies as multivariable, prediction research

K G M Moons, D E Grobbee

Patient outcomes in diagnostic research

Opinion

Test Research versus Diagnostic Research

Moons et al. Epidemiology 1999

Moons et al. JECH 2002

Summer Session in Epidemiology and Biostatistics 2008

Advanced Diagnostic Research
A special course jointly sponsored by Epidemiology & Biostatistics, and the CIHR Strategic Training Centre in Infectious Diseases and Autoimmunity. McGill Centre for the Study of Host Resistance

Academic credits: 2
Dates: May 6 - 9, 2008
Class times: 9 - 4:30 PM, Tuesday through Friday
Course instructor: Professor Karel Moons, MD, PhD (University Medical Center, Utrecht, The Netherlands)
Course coordinator: Dr. Madhuwar Pai, MD, PhD (madhuwar.pai@mcgill.ca)
Enrollment limit: 20

Description: Diagnostic research is often focused on estimating the sensitivity and specificity of diagnostic tests. This course will demonstrate that this so-called "test research" is not necessarily the same as diagnostic research. Furthermore, we will widen the horizons by presenting methods of diagnostic study design and of data analysis in which the patient's test result can be considered in the context of his or her set of individual characteristics and prior test results. These methods enable both direct estimation of individual probabilities of disease presence based on all diagnostic information and the evaluation of the extent to which a test can aid in the clinical setting. The course will include hands-on computer labs.

Course content: Principles of diagnostic research, design of diagnostic studies, data-analysis in diagnostic research and development of risk scores, and meta analyses of diagnostic studies.

Prerequisites: This is an advanced course, and prior coursework in intermediate epidemiology and biostatistics is required (specifically, knowledge of multivariable logistic regression). Students without prior coursework in multivariable methods will not be permitted to register.

Course materials: All participants will receive a course-pack with articles, readings, labs, etc.

Instructor: Karel G.M. Moons is Professor of Clinical Epidemiology at the Julius Center for Health Sciences and Primary Care at Utrecht, Netherlands. His main focus concerns the methodology of diagnostic research. His major expertise is testing existing and introducing innovative designs and analytical methods for the evaluation of diagnostic tests, and the development, validation and implementation of diagnostic and prognostic prediction rules. He teaches courses on advanced diagnostic research throughout the world. He has over 150 publications and has obtained numerous grants and awards in the field.

Note: The language of instruction is English, and students are advised that fluency in English is essential to benefit from the course. However, students may submit their course assignments and examinations in French. Courses may be taken for Academic Credit, Continuing Medical Education (CME) Credit, or for a Professional Interest Certificate.
Multivariable approach

Key outcome here is what is the added value of a new test, beyond all the prior tests that may have been done (including history/physical).

**FIGURE 3.3** Example of an ROC curve of the reduced multivariable logistic regression model, including the same six determinants as in Figure 3.2. The ROC area of the "reduced history + physical model" (red) was 0.70 (95% confidence interval [CI], 0.66–0.74) and of the same model added with the D-dimer assay (green) 0.84 (95% CI, 0.80–0.88).

The multivariable approach mimics the real life diagnostic process

1. A diagnosis starts with a patient presenting a complaint (symptom and/or sign) suggestive of a certain disease to be diagnosed.

2. The subsequent work-up is a multivariable process. It involves multiple diagnostic determinants (tests) that are applied in a logical order: from age, gender, medical history, and signs and symptoms, to more complicated, invasive, and costly tests.

3. Setting or ruling out a diagnosis is a probabilistic action in which the probability of the presence or absence of the disease is central. This probability is continuously updated based on subsequent diagnostic test results.

4. The true diagnostic value of a test is determined by the extent to which it provides diagnostic information beyond earlier tests, that is, materially changes the probability estimation of disease presence based on previous test results.

5. The goal of the diagnostic process is to eventually rule in or out the disease with enough confidence to take clinical decisions. This requires precise estimates of the probability of the presence of the target disease(s).
